Skip to main content

Silexion Therapeutics Corp

SLXNW
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002022416

No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $70.3K in total; no superinvestor holds it.

Other share classesSLXN

Q4 2025 vs. Q3 2025

How the institutions holding Silexion Therapeutics Corp changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of SLXNW: Q3 2025 compared with Q4 2025
MeasureQ3 2025Of which not filed for Q4 2025Q4 2025Change
Holders22122+1
Shares2.56M10.0K2.37M−182.3K (−7.1%)
Value$89.8K$352$61.8K−$27.6K (−30.9%)

1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (2)

Institutions that held Silexion Therapeutics Corp at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to SLXNW in Q4 2025
InstitutionSharesValue% of portfolio
Blue Owl Capital Holdings LP12,500$3750.00%
HRT Financial LP21,260$00.00%

Sold out (1)

Institutions that held Silexion Therapeutics Corp at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of SLXNW in Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
Susquehanna International Group, LLP220,053$7.75K

Not filed for Q4 2025 yet (1)

Institutions that held Silexion Therapeutics Corp at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SLXNW in Q3 2025 that haven't filed for Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
Cobblestone Capital Advisors LLC10,000$352